Status:
COMPLETED
PERsonal ContExtual Precision healTh
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
University of California, Davis
California Initiative to Advance Precision Medicine
Conditions:
Hypertension
Depression
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The exponential growth of physiological, behavioral and environmental data generated through consumer mobile health (mHealth) devices and Internet of Things (IoT) technology provide unprecedented sour...
Eligibility Criteria
Inclusion
- Primary care patient at UCD or UCSF
- Able to speak and read English
- Male or female 18-80 years of age at Telephone screening
- Documentation of a diagnosis of hypertension (defined as SBP \>= 140 mmHg or DBP \>= 90 mmHg on anti-hypertensive medication including beta-blockers, ACE-I, ARB, alpha-blockers, calcium-channel blockers) OR depression (PHQ-8 \> 5) on an antidepressant medication
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
- Have an Android or Apple iOS smartphone
- Willing to install the PERCEPT, iHealth (for hypertension cohort) and Moves mobile applications
- Willing to self-report blood pressure (for those with hypertension and with provided iHealth and/or standard blood pressure cuff) or mood data (for those with depression) at specified frequency
- Willing to be have your location and activity tracked
- Have downloaded a mobile application from the appropriate mobile app store (App store for iPhones or Google Play for Android) within the past 1 year
- Have home Wifi access.
Exclusion
- High blood pressure or depression being managed by a physician outside of UCD or UCSF
- Current participation in any other mobile app-based clinical study
- A diagnosis of both hypertension and depression
- A diagnosis of depression with psychosis (ICD-9: 296.24, 296.34) bipolar disorder (ICD-9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 296.9) schizophrenia (ICD-9: 295.x), schizoaffective disorder (ICD-9 295.70)
- Planning to relocate from area within the study duration
- Impaired vision that could limit the use of the mobile apps (participant-reported)
- Primary care patient of the Investigator, Dr. Meghana Gadgil
Key Trial Info
Start Date :
November 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT03349918
Start Date
November 6 2017
End Date
December 31 2018
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143